온전한 전이성 뇌 질환 치료를 위한 단일 분할 정위 방사선 수술과 분할 정위 방사선 수술 비교, FRACTIONATE 시험
온전한 전이성 뇌 질환(FRACTIONATE)에 대한 분할 SRS(FSRS)와 비교한 단일 분할 정위 방사선 수술(SRS)의 1상 IIR 시험
This phase II trial compares the effect of single fraction stereotactic radiosurgery to fractionated stereotactic radiosurgery for the treatment of patients with cancer that has spread to the brain (metastatic brain disease). Stereotactic radiosurgery (SRS) is a form of radiation therapy that focuses high-power energy on a small area of the body. This trial is being done to determine if single (one) fraction stereotactic radiosurgery is better than fractionated stereotactic radiosurgery or vice versa in controlling tumor and side effects in patients with tumors that have spread to the brain.
연구 개요
상태
상세 설명
PRIMARY OBJECTIVE:
I. To ascertain if the composite endpoint of cumulative treatment failure, defined by time to either local failure or symptomatic radiation brain necrosis of the largest brain metastasis (target lesion), is increased with fractionated stereotactic radiosurgery (FSRS) compared to single fraction stereotactic radiosurgery (SSRS).
SECONDARY OBJECTIVES:
I. To ascertain whether there is improved overall survival in patients who undergo FSRS compared to patients who receive SSRS.
II. To tabulate and descriptively compare the post-treatment adverse events associated with the interventions, including the potential impact of immunotherapy and targeted therapy.
III. To compare rates of radiation necrosis in patients who receive FSRS to patients who receive SSRS.
IV. To evaluate if there is any difference in central nervous system (CNS) failure patterns (e.g. local, distant brain failure) in patients who receive FSRS compared to patients who receive SSRS.
V. To ascertain whether FSRS prolongs time to neurologic death as compared to SRS.
VI. To determine whether there is improved patient reported outcomes (Functional Assessment of Cancer Therapy [FACT]-Brain Symptom Index [FBrSI]-24) including quality of life for patients who receive FSRS compared to patients who receive SSRS.
VII. To evaluate if there is any difference in CNS failure patterns (e.g. local, distant brain failure) and symptomatic radiation necrosis rates in patients who are treated with gamma knife compared to patients who are treated with a linear accelerator platform.
VIII. To determine whether differences in time to local failure, time to necrosis, or their composite endpoint cumulative treatment failure differs between treatment arms (or other patient or treatment factors) when analyzed on a "per lesion" basis rather than the per patient basis utilized for the primary endpoint.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients undergo single fraction SRS. Patients also undergo magnetic resonance imaging (MRI) at screening and during follow up.
ARM B: Patients undergo fractionated SRS, for 3-5 treatments, given over no more than 8 days. Patients also undergo MRI at screening and during follow up.
After completion of study treatment, patients are followed up at 3 months, every 3 months for 2 years, and then every 6 months for 3 years.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
연구 장소
-
-
Arizona
-
Scottsdale, Arizona, 미국, 85259
- 모병
- Mayo Clinic in Arizona
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- Sujay A. Vora, MD
-
-
Florida
-
Jacksonville, Florida, 미국, 32224
- 모병
- Mayo Clinic in Florida
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- Jennifer L. Peterson, MD
-
-
Minnesota
-
Albert Lea, Minnesota, 미국, 56007
- 아직 모집하지 않음
- Mayo Clinic Health System in Albert Lea
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- John Yeakel, MD
-
연락하다:
- Lori Rhodes
- 전화번호: 507-284-0063
- 이메일: Rhodes.Lori@mayo.edu
-
Mankato, Minnesota, 미국, 56001
- 모병
- Mayo Clinic Health Systems-Mankato
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
연락하다:
- Lori Rhodes
- 전화번호: 507-284-0063
- 이메일: Rhodes.Lori@mayo.edu
-
수석 연구원:
- Jason T. Hayes, MD
-
Rochester, Minnesota, 미국, 55905
- 모병
- Mayo Clinic in Rochester
-
수석 연구원:
- Paul D. Brown, M.D.
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
-
Wisconsin
-
Eau Claire, Wisconsin, 미국, 54701
- 모병
- Mayo Clinic Health System-Eau Claire Clinic
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- Now Bahar Alam, MD
-
연락하다:
- Lori Rhodes
- 전화번호: 507-284-0063
- 이메일: Rhodes.Lori@mayo.edu
-
La Crosse, Wisconsin, 미국, 54601
- 모병
- Mayo Clinic Health System-Franciscan Healthcare
-
연락하다:
- Clinical Trials Referral Office
- 전화번호: 855-776-0015
- 이메일: mayocliniccancerstudies@mayo.edu
-
수석 연구원:
- Abigail L. Stockham, MD
-
연락하다:
- Lori Rhodes
- 전화번호: 507-284-0063
- 이메일: Rhodes.Lori@mayo.edu
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Age >= 18 years old
-
Presence of presumed brain metastases from an extra-cerebral tumor site (e.g. lung, breast, prostate, etc.)
- Note: Dural based metastases (e.g. commonly seen in breast cancer) are eligible
-
Size of brain metastases
- At least one intact metastasis (not previously treated with radiosurgery) must measure >= 2.0 cm and =< 4.0 cm in maximal extent on the contrasted pre-treatment magnetic resonance imaging (MRI) brain scan obtained =< 28 days prior to registration
- If the largest lesion measures >= 2.0 to =< 4.0 cm in maximal extent the patient will be randomized
-
Able to undergo contrast enhanced MRI brain
-
Negative urine or serum pregnancy test completed =< 7 days prior to registration, for women of childbearing potential only
-
Patient is willing and able to provide written informed consent or have a legally Authorized Representative (LAR) who is responsible for the care and well-being of the potential study participant provide consent.
-
Karnofsky performance status (KPS) >= 50
-
Eastern Cooperative Oncology Group (ECOG) performance score of (PS) >= 2
-
Past radiosurgery or resection is allowed as long as no definitive evidence of progression in these locations
- Note: Repeat radiosurgery to the same location/lesion is not allowed on this protocol
Exclusion Criteria:
-
Any patient who has received previous whole brain radiation
-
Any brain metastasis that is located in the brainstem measuring >= 2.0 cm in maximal extent
-
Any patient with definitive evidence of leptomeningeal metastasis (LMD)
- NOTE: For the purposes of exclusion, LMD is a clinical diagnosis, defined as positive cerebrospinal fluid (CSF) cytology and/or unequivocal radiologic or clinical evidence of leptomeningeal involvement. Patients with leptomeningeal symptoms in the setting of leptomeningeal enhancement by imaging (MRI) would be considered to have LMD even in the absence of positive CSF cytology, unless a parenchymal lesion can adequately explain the neurologic symptoms and/or signs. In contrast, an asymptomatic or minimally symptomatic patient with mild or nonspecific leptomeningeal enhancement (MRI) would not be considered to have LMD. In that patient, CSF sampling is not required to formally exclude LMD, but can be performed at the investigator's discretion based on level of clinical suspicion
-
Any patient with an intact brain metastasis measuring > 4.0 cm
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: Arm A (single fraction SRS)
Patients undergo single fraction SRS. Patients also undergo MRI at screening and during follow up. |
Undergo MRI
다른 이름들:
Ancillary studies Undergo single fraction SRS
다른 이름들:
Undergo fractionated SRS
다른 이름들:
|
|
다른: Arm B (fractionated SRS)
Patients undergo fractionated SRS, for 3-5 treatments, given over no more than 8 days.. Patients also undergo MRI at screening and during follow up. |
Undergo MRI
다른 이름들:
Ancillary studies Undergo single fraction SRS
다른 이름들:
Undergo fractionated SRS
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to local failure or symptomatic radiation brain necrosis of large brain metastasis
기간: Up to 5 years
|
Will determine if the composite endpoint of time to local failure or symptomatic radiation brain necrosis of a large brain metastasis [cumulative treatment failure (CTF)] is increased with fractionated stereotactic radiosurgery (FSRS) compared to single fraction stereotactic radiosurgery (SSRS). |
Up to 5 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall survival (OS)
기간: From study entry to death from any cause, assessed up to 5 years
|
OS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. Medians and 95% confidence intervals will be reported. |
From study entry to death from any cause, assessed up to 5 years
|
|
Incidence of adverse events
기간: Up to 2 years post radiation therapy
|
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test. |
Up to 2 years post radiation therapy
|
|
Rates of radiation necrosis
기간: Up to 5 years
|
Will compare rates of radiation necrosis in patients who receive FSRS to patients who receive SSRS. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test. |
Up to 5 years
|
|
Central nervous system (CNS) failure patterns (Fractionation)
기간: Up to 5 years
|
Will evaluate if there is any difference in CNS failure patterns (e.g. local, distant brain failure) in patients who receive FSRS compared to patients who receive SSRS. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test. |
Up to 5 years
|
|
Time to neurologic death
기간: Up to 5 years
|
Will ascertain whether FSRS prolongs time to neurologic death as compared to SSRS. This will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. Medians and 95% confidence intervals will be reported. |
Up to 5 years
|
|
Quality of life (QOL)
기간: Up to 5 years
|
Will determine whether there are improved patient reported outcomes (Functional Assessment of Cancer Therapy [FACT]-Brain Symptom Index [FBrSI]-24) including quality of life for patients who receive FSRS compared to patients who receive SSRS. Changes over time in QOL from baseline will be compared between arms using the 2-sample t-test (or Wilcoxon Rank-Sum test for non-normal data). Box-plots will be used to show differences between arms graphically. |
Up to 5 years
|
|
CNS failure patterns (Gamma Knife)
기간: Up to 5 years
|
Will evaluate if there is any difference in CNS failure patterns (e.g. local, distant brain failure) and symptomatic radiation necrosis rates in patients who are treated with Gamma Knife compared to patients who are treated with a linear accelerator platform. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test. |
Up to 5 years
|
|
Per lesion analysis between treatment arms: time to local failure
기간: Up to 5 years
|
Will determine whether differences in time to local failure differs between treatment arms (or other patient or treatment factors) when analyzed on a "per lesion" basis rather than the per patient basis utilized for the primary endpoint. Time-to-event models (Cox and Kaplan- Meier) with sandwich estimators for covariance will be utilized to in treatment comparisons, with model comparisons completed through log-likelihood and Akaike Information Criterion. |
Up to 5 years
|
|
Per lesion analysis between treatment arms: time to necrosis
기간: Up to 5 years
|
Will determine whether differences in time to necrosis differs between treatment arms (or other patient or treatment factors) when analyzed on a "per lesion" basis rather than the per patient basis utilized for the primary endpoint. Time-to-event models (Cox and Kaplan- Meier) with sandwich estimators for covariance will be utilized to in treatment comparisons, with model comparisons completed through log-likelihood and Akaike Information Criterion. |
Up to 5 years
|
|
Per lesion analysis between treatment arms: endpoint CTF
기간: Up to 5 years
|
Will determine whether differences in the composite endpoint CTF differs between treatment arms (or other patient or treatment factors) when analyzed on a "per lesion" basis rather than the per patient basis utilized for the primary endpoint. Time-to-event models (Cox and Kaplan- Meier) with sandwich estimators for covariance will be utilized to in treatment comparisons, with model comparisons completed through log-likelihood and Akaike Information Criterion. |
Up to 5 years
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Paul D. Brown, MD, Mayo Clinic in Rochester
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- GMROR2163
- NCI-2021-14230 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- 21-003768 (기타 식별자: Mayo Clinic Institutional Review Board)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .